TY  - JOUR
AU  - Pico, Sara
AU  - Parras, Alberto
AU  - Santos-Galindo, Maria
AU  - Pose-Utrilla, Julia
AU  - Castro, Margarita
AU  - Fraga, Enrique
AU  - Hernandez, Ivo H
AU  - Elorza, Ainara
AU  - Anta, Hector
AU  - Wang, Nan
AU  - Marti-Ssnchez, Laura
AU  - Belloc, Eulalia
AU  - Garcia-Esparcia, Paula
AU  - Garrido, Juan J
AU  - Ferrer, Isidro
AU  - Macias-Garcia, Daniel
AU  - Mir, Pablo
AU  - Artuch, Rafael
AU  - Perez, Belen
AU  - Hernandez, Felix
AU  - Navarro, Pilar
AU  - Lopez-Sendon, Jose Luis
AU  - Iglesias, Teresa
AU  - Yang, X William
AU  - Mendez, Raul
AU  - Lucas, Jose J
PY  - 2021
DO  - 10.1126/scitranslmed.abe7104
UR  - https://hdl.handle.net/10668/27034
T2  - Science translational medicine
AB  - Huntington’s disease (HD) is a hereditary neurodegenerative disorder of the basal ganglia for which disease-modifying treatments are not yet available. Although gene-silencing therapies are currently being tested, further molecular mechanisms must be...
LA  - en
PB  - American Association for the Advancement of Science (AAAS)
KW  - Humans
KW  - Huntington Disease
KW  - Transcription Factors
KW  - mRNA Cleavage and Polyadenylation Factors
KW  - Humans
KW  - Huntington Disease
KW  - Membrane Transport Proteins
KW  - Polyadenylation
KW  - Transcription Factors
KW  - Transcriptome
KW  - mRNA Cleavage and Polyadenylation Factors
TI  - CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington's disease.
TY  - research article
VL  - 13
ER  -